EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Janus Kinase Inhibitors for the Treatment of Pediatric Morphea: A Systematic Review

Alexa Moschella iD, Celina DeBiasio iD, Carmen Liy-Wong iD

Pediatric Dermatology · 2026-05 · 43 (3) · 654-656

DOI: 10.1111/pde.70090 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Pediatric Dermatology, online erschienen am 18.11.2025. Verfasst von Alexa Moschella und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Scleroderma, Localized, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Morphea, also known as localized scleroderma (LoS), is an inflammatory, fibrosing dermatologic disorder of the skin and underlying tissues with associated comorbidities including joint contractures, limb‐length discrepancies, and inflammatory arthropathy occurring more commonly in children. While standardized consensus treatment plans for pediatric LoS have been developed by the Childhood Arthritis and Rheumatology Research Alliance, the use of Janus kinase (JAK) inhibitors in the treatment of pediatric LoS has recently been reported. This review, which systematically summarizes the published literature on the use of oral and topical JAK inhibitors for pediatric LoS, identified nine studies (involving 16 patients across all studies) that met inclusion criteria with improvement following JAK inhibitor initiation reported in 94% ( n = 15) of cases. Overall, these findings demonstrate that JAK inhibitors may offer a promising alternative to treat pediatric morphea; however, more robust studies are required to evaluate the efficacy of JAK inhibitors in treating pediatric LoS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, LocalizedJanus Kinase InhibitorsHumansChildTreatment OutcomeAdministration, Oral

Stichwörter der Autor:innen

Janus kinase inhibitorslocalized sclerodermamethotrexatemorphea

Substanzen

Janus Kinase Inhibitors

Autor:innen und Institutionen

  • Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Division of Dermatology, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Division of Dermatology and Rheumatology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.

ORCID-Profile: Alexa Moschella, Celina DeBiasio, Carmen Liy-Wong

Zitieren

APA

Moschella, A., DeBiasio, C., & Liy-Wong, C. (2026). Janus Kinase Inhibitors for the Treatment of Pediatric Morphea: A Systematic Review. Pediatric Dermatology, 43(3), 654-656. https://doi.org/10.1111/pde.70090

Vancouver

Moschella A, DeBiasio C, Liy-Wong C. Janus Kinase Inhibitors for the Treatment of Pediatric Morphea: A Systematic Review. Pediatric Dermatology. 2026;43(3):654-656. doi:10.1111/pde.70090

BibTeX
@article{Moschella2026,
  author = {Moschella, Alexa and DeBiasio, Celina and Liy-Wong, Carmen},
  title = {Janus Kinase Inhibitors for the Treatment of Pediatric Morphea: A Systematic Review},
  journal = {Pediatric Dermatology},
  year = {2026},
  volume = {43},
  number = {3},
  pages = {654--656},
  doi = {10.1111/pde.70090}
}
Kostenlos starten →